Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation

This publication has 21 references indexed in Scilit:

• High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration
  British Journal of Cancer, 1997
• A controlled trial of recombinant human erythropoietin after bone marrow transplantation
  Blood, 1994
• Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation
  British Journal of Haematology, 1994
• Impaired erythropoietin response to anemia after bone marrow transplantation
  Blood, 1992
• Changes in serum erythropoietin levels during allogeneic bone marrow transplantation
  European Journal of Haematology, 1991
• Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants
  Blood, 1991
• Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy
  Blood, 1990
• Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients
  British Journal of Haematology, 1990
• Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation
  British Journal of Haematology, 1989
• Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
  New England Journal of Medicine, 1987